Moreover, LAG3 was mainly expressed in NK cells, which indicated that combined knockdown of SLC25A39 in CRC cells and chimeric antigen receptor NK-cells immunotherapy targeted to LAG3 might also be an effective strategy in CRC immunotherapy. This evidence concerns the gene LAG3 and colorectal carcinoma.